TGNA News and Press, TEGNA Inc From 01/22/24

2024-01-22 14:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Strasbourg, France, January 22, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of James Wentworth, PhD, MBA, as Chief Business Officer ...

Strasbourg (France), January 22, 2024 - 08:00 am CET TRANSGENE (Paris: TNG) today announced its financial reporting dates for 2024. March 27, 2024: 2023 Fiscal Year Results May 14, 2024: First Quarter 2024 Financial Results May 15, 2024: Annual Shareholders' Meetin...

2024-01-15 01:13:24 ET More on TEGNA TEGNA: Large Buyback Should Begin To Lift Shares In 2024 TEGNA Inc. (TGNA) Q3 2023 Earnings Call Transcript TEGNA Inc. 2023 Q3 - Results - Earnings Call Presentation TEGNA enters into $325 million accelerated share repurch...

DIRECTV and TEGNA Reach New Multi-Year Distribution Agreement PR Newswire EL SEGUNDO, Calif. , and TYSONS, Va. , Jan. 13, 2024 /PRNewswire/ -- DIRECTV and TEGNA have reached a new multi-year distribution agreement covering TEGNA's 64 owned stations in 51 Nielsen ...

TEGNA Inc. (NYSE: TGNA) will host a conference call to discuss its fourth quarter and full-year 2023 earnings results on Thursday, February 29, 2024, at 10 a.m. (ET). The conference call will be webcast through the company’s website , and is open to investors, the financial communi...

2024-01-08 21:27:53 ET Summary TEGNA stock has underperformed due to failed acquisition and concerns about the future of television. TEGNA's geographic mix and political advertising revenue make it a likely beneficiary of the 2024 election cycle. TEGNA's strong cash flow, shar...

Transgene and NEC plan to start an extension of the randomized Phase I trial into a randomized Phase I/II study in 2024 to further demonstrate the potential of TG4050 as an adjuvant treatment of head and neck cancers Strasbourg, France & Tokyo, Japan, January 8, 2024, 5:45 ...

TEGNA Inc. (NYSE: TGNA) today announced that the 2024 Annual Meeting of Shareholders will be held on Wednesday, April 24, 2024, at 9 a.m. (ET). Shareholders of record as of the close of business on February 26, 2024, will be notified of the meeting and will be eligible to vote. The Annual Mee...

2023-12-27 23:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...